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Long-term Mortality in Adult Orthotopic Heart Transplant 
Recipients
Heart transplantation is now regarded as the treatment of choice for end-stage heart 
failure. To improve long-term results of the heart transplantation, we analyzed causes of 
death relative to time after transplantation. A total of 201 consecutive patients, 154 
(76.6%) males, aged ≥ 17 yr underwent heart transplantation between November 1992 
and December 2008. Mean ages of recipients and donors were 42.8 ± 12.4 and 29.8 ± 
9.6 yr, respectively. The bicaval anastomosis technique was used since 1999. Mean follow 
up duration was 6.5 ± 4.4 yr. Two patients (1%) died in-hospital due to sepsis caused by 
infection. Late death occurred in 39 patients (19.4%) with the most common cause being 
sepsis due to infection. The 1-, 5-, and 10-yr survival rates in these patients were 95.5% ± 
1.5%, 86.9% ± 2.6%, and 73.5% ± 4.1%, respectively. The surgical results of heart 
transplantation in adults were excellent, with late mortality due primarily to infection, 
malignancy, and rejection. Cardiac deaths related to cardiac allograft vasculopathy were 
very rare.
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INTRODUCTION
Heart failure is related primarily to advanced age (1, 2). The num-
ber of patients with end-stage heart failure has been increasing 
due to increasing mean life expectancy. Heart transplantation 
has become the treatment of choice for patients with end-stage 
heart failure. Tremendous advances in immunosuppression, 
rejection control, and infection control have improved the re-
sults of heart transplantation (3). Currently, the operative mor-
tality rate is 5%-10% and the 1-yr survival rate is as high as 85%, 
with survival thereafter decreasing linearly (3.4% per year). The 
most common causes of death in the first 30 days after trans-
plantation are graft failure, multi-organ failure, and infection, 
with infection, graft failure, and acute rejection being the most 
common causes of death within 1 yr of transplant. After 1 yr, car-
diac allograft vasculopathy and malignancy are the most com-
mon causes of death (4). 
  Most of these studies, however, have been performed in West-
ern countries and little is known about postoperative mortality 
in Asian countries. In our institute, the first heart transplant was 
performed in 1992, with more than 200 adult heart transplanta-
tions performed since then. To improve the long-term survival 
of adult heart transplant recipients, it is important to determine 
the causes of death relative to time after transplant. We there-
fore analyzed the causes of death among patients undergoing 
heart transplantation at our institute according to post-opera-
tive period.
MATERIALS AND METHODS
Between November 1992 and December 2008, 201 adult patients 
(aged ≥ 17 yr) underwent orthotopic heart transplantation. We 
excluded patients who underwent re-transplantation. 
  The annual number of operations has been increasing, except 
around the time of settlement of Korea Organization of Nation-
al Organ Service in 2000 (Fig. 1). The mean age of recipients was 
42.8 ± 12.4 yr and 154 (76.6%) were male. Almost all patients were 
NYHA functional class III (n = 99) or IV (n = 100), except for two 
patients who were diagnosed with cardiac tumors. Three pa-
tients underwent kidney transplantation concomitantly. Two 
patients were being treated preoperatively with mechanical as-
sistance devices (extracorporeal membrane oxygenation: ECMO 
and ventricular assist device: VAD).
  The most common diagnoses requiring heart transplantation 
were dilated cardiomyopathy (n = 142, 70.6%), ischemic cardio-
myopathy (n = 22, 10.9%), and hypertrophic cardiomyopathy (n 
= 7, 3.5%). Preoperative demographic and diagnostic data are 
summarized in Table 1.
Operative techniques
In the early part of the study period, from November 1992 to 
December 1998, all operations were performed according to 
the standard technique as described by Lower et al. (5). Opera-
tive procedures of our institute were described in the previous 
report (6). Since January 1999, we have used the bicaval tech-Jung S-H, et al.  •  Long-term Mortality in Heart Transplantation
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nique described by Saram and colleagues (7, 8). Overall, the 
standard technique was used in 53 patients and the bicaval tech-
nique in 148. Myocardial protection of the donor heart was per-
formed by infusion of 2,000 mL of 4°C Custodiol
® HTK solution. 
The harvested heart was rinsed in Custodiol
® HTK solution and 
transported in the same solution in an ice box. Mean ischemic 
time was 132 ± 52 min.
Immunosuppression protocol
From November 1992 to June 1999, the preoperative immuno-
suppressive protocol, used in 60 patients, consisted of induction 
with cyclosporine 3-5 mg/kg and azathioprine 2-3 mg/kg per os 
(PO). After June 1999, the preoperative immunosuppressive pro-
tocol, used in 141 patients, consisted of anti-IL2 receptor mono-
clonal antibody (anti-IL2R mAb), mycophenolate mofetil 1.5-
2.0 g PO and administration of cyclosporine 3 mg/kg PO. Cyclo-
sporine was withheld if serum creatinine (Cr) concentration was 
greater than 1.5 mg%. Intraoperatively, methylprednisolone 500 
mg intravenous (IV) was routinely injected immediately before 
release of the aorta clamp. Postoperatively, patients were treat-
ed with mycophenolate mofetil 1-3 g/day and anti-IL2 R mAb 
to maintain a WBC count of 4,000-6,000/μL. Postoperatively, 
cyclosporine trough levels were maintained during the first year 
at 300-400 ng/mL by an enzyme-multiplied immunoassay (EMI) 
method and at 150-200 ng/mL thereafter. The initial postopera-
tive dose of prednisone was 1 mg/kg/day, decreasing to 0.25 
mg/kg/day at 1 month and to 0.1 mg/kg/day at 6 months.
Infection prophylaxis
Patients negative for HBsAg and HBsAb received HBV vaccina-
tion preoperatively. Patients also received pneumococcal vac-
cination routinely, with postoperative sulfamethoxazole and 
trimethoprim administration throughout the first year if toler-
ated. Recipients positive for cytomegalovirus (CMV) IgG received 
ganciclovir IV for 4 weeks as CMV prophylaxis. If the recipient 
CMV was IgG(-) but the donor CMV was IgG(+), recipients were 
administered IV ganciclovir for 4 weeks and then switched to 
oral ganciclovir 1.0 g three times a day for another 2-3 months. 
All patients received annual influenza vaccination. 
Endomyocardial biopsy
Endomyocardial biopsy was performed to confirm acute rejec-
tion. Biopsies were taken every week for 1 month, every month 
for 3 months, and at 6 months and 1 and 2 yr. 
Coronary angiography protocol
Cardiac allograft vasculopathy (CAV) was evaluated by coronary 
angiography and recently by concomitant intravascular ultra-
sonography (IVUS). Of the 201 patients, 188 (93.5%) had under-
gone at least one coronary angiogram (CAG), with the last CAG 
performed at a mean 4.9 ± 3.6 yr (range, 1.0-14.5 yr) after trans-
plantation. CAG was performed after more than 5 yr in 63 (31.3%) 
patients. 
Follow up
At our institute, a single expert cardiologist has been involved 
in both immediate postoperative and long-term management. 
This cardiologist selected the postoperative immunosuppres-
sion and infection protocols and hemodynamic monitoring for 
each patient. Follow-up was possible in all patients; mean fol-
low-up duration was 6.5 ± 4.4 yr. 
Statistical analysis
Data are expressed as mean ± standard deviation for continu-
ous variables, as numbers with percentage for categorical vari-
ables. Overall survival rate was estimated by the Kaplan-Meier 
method, and inter-group comparisons were performed using 
the log-rank test. A P value <0.05 was considered significant. All 
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Fig. 1. Annual trends of heart transplantation numbers in Asan Medical Center. Korea 
Organization of National Organ Service (KONOS).
Table 1. Preoperative demographic data
Characteristics   Observed
Age: Recipient (yr)   42.8 ± 12.4
Age: Donor (yr) 29.9 ± 9.7
Gender: Recipient (Male)  154 (76.6%)
Gender: Donor (Male)  157 (78.1%)
Diabetes mellitus  17 (8.5%)
Systemic hypertension 20 (10%)
Cerebrovascular accident 6 (3%)
eGFR*
   < 60 (mL/min/1.73 m
2)
  76.7 ± 28.8
   49 (24.4%)
NYHA functional class
   II
   III
   IV
Concomitant kidney transplantation
 
2 (1%)
   99 (49.3%)
 100 (49.8%)
   3 (1.5%)
Preoperative state
   Intravenous inotropes
   Mechanical cardiac support
 
   21 (10.4%)
2 (1%)
*eGFR, estimated glomerular filtration rate, calculated by the modified MDRD equation.Jung S-H, et al.  •  Long-term Mortality in Heart Transplantation
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statistical analyses were performed using SPSS version 14.0 (Ko-
rean version; SPSS, Inc., Chicago, IL, USA). 
Ethics statement
The study protocol was approved by the Institutional Review 
Board (IRB) of Asan Medical Center, Seoul, Korea (No. 2010-
0840). The requirement for informed patient consent was waived 
by the IRB owing to the retrospective nature of the current study. 
RESULTS 
Two patients (1%) died in-hospital. One patient was a 57-yr-old 
male diagnosed with dilated cardiomyopathy who underwent 
transplantation using the standard technique. Postoperatively, 
he experienced acute renal failure due to cyclosporine toxicity 
and underwent hemodialysis. Endomyocardial biopsies at 10 
and 17 days showed no evidence of acute rejection. Postopera-
tive echocardiography showed normal left and right ventricular 
function. At 16 days, he developed left lower lobe pneumonia, 
which progressed rapidly. The patient died 20 days postopera-
tively due to septic shock. 
  The second patient was a 41-yr-female who had Child class C 
cardiac cirrhosis and azotemia. She underwent transplantation 
using the bicaval technique, with a total ischemia time of 103 
min. She experienced biventricular failure postoperatively, for 
which, on day 2, an intra-aortic balloon counterpulsation (IABP) 
was inserted and continuous veno-veno hemodialysis was ap-
plied. Her heart function recovered and the IABP was removed 
3 days later. However, she developed aspergillosis and bacterial 
pneumonia. Despite aggressive medical management, this pa-
tient died 65 days after the operation. 
 
Mortality according to postoperative period
After discharge, 39 patients died. Their causes of death relative 
to postoperative period are summarized in Table 2.
  Between 1 month and 1 yr, eight patients died, including those 
who died in-hospital. The most common cause of death was 
graft failure (n = 4). In addition, two patients died due to acute 
respiratory distress syndrome caused by pneumonia, one pa-
tient died due to hepatic failure caused by the hepatitis B virus, 
and one patient committed suicide due to financial problems. 
  Between 1 yr and 5 yr, malignancy was diagnosed in two pa-
tients, one each with renal cell cancer and Kaposi’s sarcoma. 
Two patients experienced graft failure and four showed rejec-
tion of donor organs due to non-compliance with medical treat-
ment. One patient committed suicide and three died due to sep-
sis caused by infection.
  Between 5 yr and 10 yr, three patients died due to malignan-
cy, including two with T-cell lymphoma and one with lung can-
cer. One died due to organ rejection, one due to fat embolism 
after total hip replacement, and seven due to infection, includ-
ing meningitis in one patient, peritoneal dialysis infection in one, 
and pneumonia in five. One patient died due to unknown causes.
  After 10 yr, one patient died due to multiple myeloma and two 
died due to infection-related causes, one each from pneumonia 
and herpes zoster infection. The other two patients died due to 
unknown causes.
Table 2. Causes of death relative to postoperative period
Causes < 1 month < 1 yr < 5 yr < 10 yr ≥ 10 yr Total
Infection 1* 2* 3 7 2 15
Rejection 1 4 1 6
CAV 0
Malignancy 2 3 1 6
Graft failure 4 2 6
Others 1 1 1 3
Unknown 2 1 2 5
Total 1 8 14 13 5 41
*In-hospital mortality rate was one in each period. CAV, cardiac allograft vasculopathy.
Fig. 2. Overall survival rate using the Kaplan-Meier method (A) and comparison between the standard and bicaval techniques (B). YSR, year survival rate.
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  Overall survival rates were 95.5% ± 1.5% at 1 yr, 86.9% ± 2.6% 
at 5 yr, 73.5% ± 4.1% at 10 yr, and 61.6% ± 5.8% at 12 yr (Fig. 2A).
DISCUSSION
The operative mortality rate among our patients was excellent, 
especially when compared with other reports in which early 
mortality rates were 5%-10% (9, 10). The much lower mortality 
rates we observed may be related to improvements in donor 
management, the preoperative status of the recipient, and post-
operative management in the intensive care unit. 
  During the study period, there were two major changes in the 
perioperative management of heart transplant recipients, the 
use of the bicaval technique, beginning in 1999, and the intro-
duction during 1999 of an immunosuppressive regimen consist-
ing of anti-IL2R mAb and mycophenolate mofetil. Preoperative 
evaluation and postoperative management in all patients were 
directed by a single cardiologist. 
  Compared with the standard technique, the bicaval technique 
results in improved atrial function (11, 12), a lower rate of post-
operative arrhythmias (8), a reduced need for permanent pac-
ing (13), and decreased tricuspid regurgitation (14). In one se-
ries, use of the bicaval technique improved survival (15). In con-
trast, a comparison of outcomes using the bicaval and standard 
techniques in heart transplantation showed that neither was 
associated with a survival advantages (16). Although the bicaval 
technique seemed to be superior during the early postoperative 
period, we observed no differences in the long-term survival 
between the two groups (Fig. 2B). Because our immunosuppres-
sive protocol also changed during the study period, we could 
not determine whether surgical technique affected on survival.
  Traditionally, the most common causes of death during the 
first 30 days after transplantation are graft failure, multi-organ 
failure, and infection. An updated report from the registry of the 
International Society of Heart and Lung Transplantation showed 
that graft failure and infection were the most important causes 
of 30-day mortality (10). Because only 1 of our patients died, 
prior to postoperative 30 days, of infection, direct comparison 
was difficult. Our low mortality rates showed the effectiveness 
of recent advancements in myocardial protection and donor 
management.
  Infection, graft failure, and acute rejection have been regard-
ed as the most common causes of death within 1 yr after trans-
plantation. We found that infection remained an important 
cause of death during this period, whereas graft failure was more 
common during this period than other post-transplant periods. 
Four patients died due to graft failure, at onset times of about 6 
months postoperatively. Endomyocardial biopsy and echocar-
diography were performed within 1 month in two patients with 
normal contractility and no evidence of significant rejection. 
Another patient had experienced postoperative constrictive peri-
carditis.
  Infection was the predominant cause of death between 5 and 
10 yr. During this period, the incidences of graft failure and re-
jection were relatively low. Sites of infection varied and includ-
ed the lungs (pneumonia), brain (meningitis), and peritoneal 
catheters, with pneumonia being the most common cause of 
death. Four patients had malignancies, including three with 
lymphoma and one with lung cancer.
  This study had several limitations, most of them being inher-
ent to the retrospective analysis of patients in a single center. 
However, the regimen of postoperative management was con-
trolled by a single cardiologist, allowing consistent patient man-
agement during the follow-up period. The causes of death after 
heart transplantation were complex, so the assignment of a sin-
gle cause was difficult. In most cases underlying disease was 
considered to be the cause of death.
  In conclusion, the present study shows that the surgical mor-
tality rates of adults who underwent heart transplantation are 
excellent and that long-term survival is acceptable. The most 
common cause of death within 1 yr is graft failure, followed by 
infection. Notably, none of our patients died due to cardiac al-
lograft vasculopathy. Additional studies are necessary to assess 
the impact of cardiac allograft vasculopathy on survival. 
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Long-term Mortality in Adult Orthotopic Heart Transplant Recipients
Sung-Ho Jung, Jae Joong Kim, Suk Jung Choo, Tae-Jin Yun, Cheol Hyun Chung, and Jae Won Lee
Heart transplantation is the treatment of choice in patients wiht end-stage heart failure. To improve the long-term results of heart 
transplantation, we should know the causes of death after the surgery. We investigated the cases of post-operative death 
according to the time after transplantation in Korea. In-hospital mortality was 1% (2/201) and a 10-yr survival rate was 74%. The 
late mortality was primarily due to infection, malignancy, and immune rejection. The Death related with cardiac allograft 
vasculopathy was very rare. Further study would be necessary to analyze the differences of causes of death in Korea compared 
with western countries.